NCT05944198Completed
Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis
Clinical Study of 18F-labeled Probes Targeting Fibroblast Activating Protein and Integrin avβ3 (FAPI-RGD) to Assess Disease Activity in Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 15 Jul 2024
Brief summary (registry, in English)
The goal of this observational study is to learn about 18F-FAPI-RGD PET/CT imaging in assessing rheumatoid arthritis disease activity. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 6 Jul 2023
- Start date
- 14 Jul 2023
- Primary completion date
- 20 Feb 2024
- Lead sponsor
- Sichuan Provincial People's Hospital
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05944198
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 14 Jul 2023 to the primary completion date, 20 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A. Patients with malignant tumors and other rheumatic immune diseases; B. clinical and conventional radiographic inspection of materials; C. researchers think not suitable for other information to participate in this study.
Who the study is looking for
- Patients with rheumatoid arthritis who meet the 2010 American College of Rheumatology/European League Against Rheumatism Rheumatoid arthritis classification criteria.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Departments of Nuclear Medicine, Sichuan Provincial People's Hospital Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.